R&G PharmaStudies Co. Ltd. A Cash Flow Quality Index
R&G PharmaStudies Co. Ltd. A cash flow quality index. R&G PharmaStudies Co. Ltd. A (301333) has a Cash Flow Quality Index of 1.19x as of June 2022. Operating cash flow of CN¥40.98 Million exceeds net income of CN¥34.56 Million, indicating high earnings quality where cash backs reported profits. See 301333 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of R&G PharmaStudies Co. Ltd. A (2019–2025)
Cash flow quality index of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. Historical Cash Flow Quality Index for R&G PharmaStudies Co. Ltd. A across 7 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore 301333 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
R&G PharmaStudies Co. Ltd. A Cash Flow Quality Index by Year (2019–2025)
R&G PharmaStudies Co. Ltd. A cash flow quality index by year from 2019 to 2025. Year-by-year earnings quality comparison for R&G PharmaStudies Co. Ltd. A. For the full cash flow conversion analysis, see 301333 cash flow conversion.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.83x | CN¥114.20 Million | CN¥136.90 Million | ▼ -24.4% |
| 2024 | 1.10x | CN¥154.76 Million | CN¥140.22 Million | ▼ -6.8% |
| 2023 | 1.18x | CN¥192.56 Million | CN¥162.53 Million | ▲ +3.2% |
| 2022 | 1.15x | CN¥130.47 Million | CN¥113.59 Million | ▼ -0.5% |
| 2021 | 1.15x | CN¥114.57 Million | CN¥99.24 Million | ▲ +119.5% |
| 2020 | 0.53x | CN¥44.10 Million | CN¥83.84 Million | ▼ -58.0% |
| 2019 | 1.25x | CN¥103.48 Million | CN¥82.63 Million | — |